Healthy Volunteers, Normocholesterolaemic Men, Normozoospermic Men
Conditions
Keywords
Atorvastatin, Human Spermatozoa, Seminal fluid, Accessory Glands, Cholesterol, Gonadotropins,, Testosterone
Brief summary
Recently, concerns about the effect of atorvastatin intake on men fertility have been raised. However, this statin has never been investigated regarding its influence on male fertility, notably sperm quality. The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
Detailed description
The main objective is to estimate the safety of atorvastatin on fertility of normocholesterolaemic and healthy men (having normal blood lipid profile and normal sperm parameters) by analyzing its effects on sperm parameters: ejaculate volume, sperm count, total and progressive motility, percentage of typical forms. The secondary objectives are to assess the changes in: * hormonal profile: gonadotropins and testosterone plasma levels * lipid composition of sperm and seminal fluid; * spermatozoa capacitation markers * accessory glands markers. The efficacy is estimated by measuring the lipid lowering action of atorvastatin. It is expected a decrease by 20 and 40% of total cholesterol blood and LDL-cholesterol levels, respectively (total cholesterol \<1.5 g / l and LDL-cholesterol \<1g / l). Considering this protocol as a pilot study to evaluate safety and efficacy, sample size estimation was fixed considering a Fleming design at one stage. These designs with one group and multi-stages (between 1 and 5) can be seen as filtering steps leading to the decision type go/no go. With a type I error a and statistical power (1-β) equals respectively 5% and 90%, n=17 subjects were necessary to reject the hypotheses of minimal (p=0.85) and maximal (p=0.95) acceptable non-toxicity. If 1 subject or more presented a toxicity, the treatment was considered no safe. To measure the evolution of total cholesterol and LDL-cholesterol levels concerning the efficacy, n=17 subjects were necessary to show a minimal paired difference (to be detected) of 0.5 with expected standard-deviation of difference = 0.5, correlation coefficient of 0.5, a= 5% (two-sided) for a power greater than 90% (1-β=97%). Subjects are included after a screening visit (visit 0), during which routine laboratory biochemical tests are performed, an electrocardiogram is taken, blood pressure, weight and height are measured; physical examination including testis evaluation and semen parameters are analyzed according to WHO standards 1999 . The subjects take atorvastatin orally (10mg/day (d), Tahor©, Pfizer Laboratory) during 5 months allowing to study atorvastatin effects on human spermatogenesis and epididymal maturation (one cycle requiring approximately 3 months). Blood and semen parameters were measured : * before to take atorvastatin treatment (visit 1) * at the end of the therapy (visit 3) * and 3 months after the end of treatment, (visit 4) to perform measurements during different cycles of spermatogenesis on a same subject. After two months of treatment, a consultation (visit 2) is realized to ensure good tolerance to treatment and to control treatment efficiency. Biochemical clinical and semen measurements take before treatment were considered as control baseline measures.
Interventions
DRUGAtorvastatin
The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
Sponsors
Service de Biologie de la Reproduction : AMP-CECOS
EA 975, Laboratoire de BDR
Service d'Endocrinologie, Diabète et Maladies Métaboliques
Laboratoire d'Hormonologie - Biochimie
University Hospital, Clermont-Ferrand
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Men : * between 18 and 65 years ; * with normal conventional semen parameters and negative semen culture according to WHO standards 1999 : volume ejaculate ≥ 2 ml, sperm count ≥ 20millions/ml, total motility ≥ 50% progressive motility ≥ 30%, typical forms ≥ 20%; * with normal blood lipid profile: total cholesterol \< 2.50g/L, triglycerides \< 1.70g/L, HDL-C \> 0.35 g/L and LDL-C \< 2.2 g/L; * without known pathology or ongoing treatment
Exclusion criteria
* Subjects with medical or surgical history that may make them at risk during the study, * Subjects with cons-indications to taking atorvastatin * Subjects with an active liver disease or increased level of serum transaminases * Subjects with a history of allergy * Subjects whose lipid parameters do not match the inclusions criteria or receiving lipid-lowering therapy * Subject with abnormal semen analysis or cryptorchidism or a varicocele * Subjects who participated in another clinical trial or other experimentation or other tolerance study of a drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observations of all modifications on semen quality after 5 months of atorvastatin treatment | at month 5 |
| Observations of all modifications on semen quality after 5 months of atorvastatin treatment and after 3 months after its withdrawal | at month 8 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| hormonal profile: gonadotropins and total testosterone plasma levels | at month 5 | All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
| lipid composition of sperm and seminal fluid | at month 5 | All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
| spermatozoa capacitation markers | at month 5 | All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
| accessory glands markers | at month 5 | All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
Countries
France
Outcome results
None listed